Aspirin for MI primary prevention
Use of aspirin for primary prevention of myocardial infarction will be considered by FDA's Cardiovascular & Renal Drugs Advisory Committee in consultation with Nonprescription Drugs Advisory Committee on Dec. 8. Bayer asked FDA in a Feb. 11 citizen petition to allow the indication based on a meta-analysis of five studies showing a 32% reduction in MI in patients who had not previously had a cardiovascular event. The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8:30 a.m. [To 1watch a webcast of the meeting, go to FDAAdvisoryCommittee.com]...
You may also be interested in...
The sentences are the latest chapter in a long-running off-label marketing case.
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
Beximco has struck a deal worth nearly $50m to acquire a majority stake in Sanofi Bangladesh, allowing the firm to expand in its domestic market.